Haiti

Resilience System


You are here

Treatments

U.S. NIH plans first big clinical trials of treatments for long-term COVID-19

...

The National Institutes of Health is now hoping to launch its first big clinical trials of potential treatments for patients experiencing long-term symptoms from COVID-19 as early as October, according to a top federal official overseeing the plans.

...

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Who will be eligible for the upcoming Omicron-specific Covid booster shots

 

Omicron-specific Covid booster shots are just weeks away. Here’s who will—and won’t—be eligible

Newly updated Covid booster shots designed to target omicron’s BA.5 subvariant should be available within in the next three weeks. That begs an important question: Who’s going to be eligible to get them?

The short answer: Anyone ages 12 and up who has completed a primary vaccination series, a Centers for Disease Control and Prevention spokesperson tells CNBC Make It. It’s unlikely to matter whether you’ve received any other booster doses or not before, the spokesperson says — but if you’re unvaccinated, you won’t eligible for the updated formula until you complete a primary series with the existing Covid vaccines.

The longer answer is somewhat more complex, because it depends on which booster shots get approved and when. ...

 

 

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

A guide to which COVID boosters to take and when

... the range of options, which will be available at different times, has left people wondering which vaccines to take, and when. “These are hard questions, and there are no real right answers,” says Kathryn Edwards, a paediatrician and director of the Vanderbilt Vaccine Research Program at Vanderbilt University Medical Center in Nashville, Tennessee.

Nature asked specialists what evidence is on hand to help make the decision.  ...

 

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Pages

Subscribe to Treatments
howdy folks
Page loaded in 0.564 seconds.